Latest filing published 10 Mar 2023 for Ironwood Pharmaceuticals INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jason Rickard, listed as senior executive, appears in our data through filings on Ironwood Pharmaceuticals Inc shares, published by SEC (Form 4). In total, 14 filings cover trades dated from 24 May 2021 to 8 March 2023.
The open-market record consists of 10 sales worth €1.1M, with no purchase. The rest of the record consists of 4 share grants. Since January 2023: no purchases and 1 sale on the market.
The newest entry dates from 10 March 2023: a share grant, in Ironwood Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations